GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Polynovo Ltd (ASX:PNV) » Definitions » Price-to-Owner-Earnings

Polynovo (ASX:PNV) Price-to-Owner-Earnings : 117.00 (As of Apr. 24, 2025)


View and export this data going back to 1998. Start your Free Trial

What is Polynovo Price-to-Owner-Earnings?

As of today (2025-04-24), Polynovo's share price is A$1.17. Polynovo's Owner Earnings per Share (TTM) ended in Jun. 2024 was A$0.01. It's Price-to-Owner-Earnings for today is 117.00.


The historical rank and industry rank for Polynovo's Price-to-Owner-Earnings or its related term are showing as below:

ASX:PNV' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 130   Med: 268.75   Max: 330
Current: 139.38

During the past 13 years, the highest Price-to-Owner-Earnings of Polynovo was 330.00. The lowest was 130.00. And the median was 268.75.


ASX:PNV's Price-to-Owner-Earnings is ranked worse than
89.08% of 284 companies
in the Medical Devices & Instruments industry
Industry Median: 28.385 vs ASX:PNV: 139.38

As of today (2025-04-24), Polynovo's share price is A$1.17. Polynovo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.01. Therefore, Polynovo's PE Ratio (TTM) for today is 130.00.

As of today (2025-04-24), Polynovo's share price is A$1.17. Polynovo's EPS without NRI for the trailing twelve months (TTM) ended in was A$0.01. Therefore, Polynovo's PE Ratio without NRI for today is 130.00.

During the past 13 years, Polynovo's highest PE Ratio without NRI was 330.00. The lowest was 116.11. And the median was 268.75.


Polynovo Price-to-Owner-Earnings Historical Data

The historical data trend for Polynovo's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polynovo Price-to-Owner-Earnings Chart

Polynovo Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 306.25

Polynovo Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 306.25 -

Competitive Comparison of Polynovo's Price-to-Owner-Earnings

For the Medical Devices subindustry, Polynovo's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Polynovo's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Polynovo's Price-to-Owner-Earnings falls into.


;
;

Polynovo Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Polynovo's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.17/0.01
=117.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Polynovo  (ASX:PNV) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Polynovo Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Polynovo's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Polynovo Business Description

Traded in Other Exchanges
Address
320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Polynovo Headlines

No Headlines